Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ZYDUSLIFE.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ZYDUSLIFE.BO and 80,000+ other tickers.
See exactly how ZYDUSLIFE.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ZYDUSLIFE.BO and 80,000+ other tickers.
Zydus Lifesciences Limited is a global pharmaceutical enterprise dedicated to the research, development, manufacturing, marketing, and distribution of medicinal products across India, the United States, and international markets. Its operations are structured into two main divisions: Pharmaceuticals and Consumer Products. The pharmaceutical segment offers a broad spectrum of human-use finished dose drugs, including generics, branded generics, specialized formulations like biosimilars and vaccines, and active pharmaceutical ingredients (APIs). It focuses on therapeutic areas such as pain…
No recent news available.